Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial

• Published in: Daru Vol. 21; no. 1; p. 8
• Main Authors: Fallahi, Babak, Beiki, Davood, Akbarpour, Saeed, Gholamrezanezhad, Ali, Fard-Esfahani, Armaghan, Akhzari, Fariba, Izadyar, Sina, Esmaeli, Javad, Saghari, Mohsen, Eftekhari, Mohammad
• Format: Journal Article
• Language: English
• Published: London BioMed Central 15.01.2013; BioMed Central Ltd
• Subjects: Adrenergic beta blockers; Biomedical and Life Sciences; Biomedicine; Clinical trials; Complications and side effects; Coronary heart disease; Diagnosis; Diagnostic imaging; Dipyridamole; Dosage and administration; Health aspects; Medical research; Medicinal Chemistry; Medicine, Experimental; Myocardial perfusion imaging; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Research Article; Risk factors; Iran; Tc-MIBI; Myocardial perfusion imaging; Coronary artery disease; Beta-blocker; Dipyridamole
• ISSN: 1560-8115; 2008-2231; 2008-2231
• DOI: 10.1186/2008-2231-21-8

Background Although it has been shown that acute beta-blocker administration may reduce the presence or severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential effect of chronic beta-blocker treatment on the sensitivity of dipyridamole myocardial perfusion imaging (DMPI). Methods As a randomized clinical trial, one hundred twenty patients (103 male and 17 female) with angiographically confirmed CAD who were on long-term beta blocker therapy (≥3 months) enrolled in a randomized clinical trial study. The patients were allocated into two groups: Group A (n=60) in whom the beta-blocker agent was discontinued for 72h before DMPI and Group B (n=60) without discontinuation of beta-blockers prior to DMPI. Results No significant difference was noted between the groups concerning age, sex, type of the injected radiotracer and number of involved coronary vessels. The mean rank of total perfusion scores for whole myocardium (irrespective of reversibility or irreversibility) in group B was not significantly different from that of group A, (65.75 vs. 55.25, P=0.096). Regarding the only irreversible perfusion defects, the mean rank of perfusion score in group B was higher than that of group A for whole myocardium (72 vs. 49, P=0.0001); however, no difference was noted between two groups for only reversible perfusion defects (61.0 vs. 60.0, P=0.898). The overall sensitivity of DMPI for the diagnosis of CAD in group A (91.7%) was not statistically different from group B (90%). Conclusion Beta-blocker withholding before DMPI did not generally affect the sensitivity of the test for the diagnostic purposes in our study. Thus, beta-blocker withdrawal for just the purpose of diagnostic imaging is not mandatory particularly when medication discontinuation may cause the patients to face increased risk of heart events.